Dataset Information

An ITRAQ-Based Quantitative Proteomics Analysis of the Hepatoprotective Effect of Melatonin on ANIT-Induced Cholestasis in Rats.

ABSTRACT: The aim of the present study was to investigate the therapeutic mechanism of the anti-cholestatic effects of melatonin against ANIT-induced liver injury in rats, and to screen for potential biomarkers of cholestasis through isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomics.

ORGANISM(S): Rattus Norvegicus

SUBMITTER: Xianggen Zhong

PROVIDER: PXD023155 | iProX | Wed Dec 16 00:00:00 GMT 2020

REPOSITORIES: iProX

ACCESS DATA

Publications

iTRAQ-based quantitative proteomics analysis of the hepatoprotective effect of melatonin on ANIT-induced cholestasis in rats.

Wang Dingnan D Yu Han H Li Yunzhou Y Xu Zongying Z Shi Shaohua S Dou Dou D Sun Lili L Zheng Zhili Z Shi Xinghua X Deng Xiulan X Zhong Xianggen X

Experimental and therapeutic medicine 20210715 3

The therapeutic effects of melatonin on cholestatic liver injury have received widespread attention recently. The aim of the present study was to investigate the mechanisms of the anti-cholestatic effects of melatonin against α-naphthyl isothiocyanate (ANIT)-induced liver injury in rats and to screen for potential biomarkers of cholestasis through isobaric tags for relative and absolute quantitation (iTRAQ) proteomics. Rats orally received melatonin (100 mg/kg body weight) or an equivalent volum ...[more]

PMID: 34373700

Similar Datasets

Project description:Intervention 1: Intervention group: Treatment with melatonin will be started on the evening of the first chemotherapy dose and continue through 1 month following the last dose of chemotherapy or 6 months after starting melatonin (each one goes earlier). During this period, patients will consume 20 mg of melatonin (4 capsules, each one contains 5mg melatonin) every evening. Melatonin capsule will be supplied by Zahravi Pharmaceutical Company. Intervention 2: Control group: Treatment with melatonin will be started on the evening of the first chemotherapy dose and continue through 1 month following the last dose of chemotherapy or 6 months after starting melatonin/placebo (each one goes earlier). During this period, patients will consume 4 capsules of placebo every evening. Placebo capsules will be supplied by Zahravi Pharmaceutical Company and will be the same as melatonin. Primary outcome(s): Percent of grade 2 and 3 neuropathy according to National Cancer Institute’s Common Toxicity Criteria for adverse events (NCI-CTCAE V.4) will be compered among the two study groups (case and control), as the main outcome of the study. Timepoint: Prior to the start of study; during the chemotherapy (prior to receiving each cycle); 1 month after receiving the last dose of chemotherapy or 6 months after initiation of melatonin (each one happens earlier). Method of measurement: National Cancer Institute’s Common Toxicity Criteria for adverse events (NCI-CTCAE V.4) scale will be used by the oncologist to evaluate severity of neuropathy in the patients. According to this scale severity of neuropathy will be classified from 1 to 5. Study Design: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization will be done by block-permutation method, considering 8 blocks, each one consisting 10 patients. Random Allocation software will be used to allocate patients to drug or placebo group. Randomization and allocation will be done by one of the researchers who has no role in the treatment and evaluation of the patients, and also analysis of data, Blinding description: Randomization and allocation will be done by one of the researchers who has no role in the treatment and evaluation of the patients, and also analysis of data. Drug (melatonin) and placebo packaging will be similar and will not be distinguishable by physician and patients who receive them. During the study, melatonin and placebo will be supplied by the same company.

Dataset Information

An ITRAQ-Based Quantitative Proteomics Analysis of the Hepatoprotective Effect of Melatonin on ANIT-Induced Cholestasis in Rats.

Publications

iTRAQ-based quantitative proteomics analysis of the hepatoprotective effect of melatonin on ANIT-induced cholestasis in rats.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure